Singapore markets open in 5 hours 27 minutes

Straits Times Index
3,239.03
+26.39(+0.82%)
S&P 500
3,990.23
+19.24(+0.48%)
Dow
32,525.27
+287.74(+0.89%)
Nasdaq
11,806.63
-17.33(-0.15%)
Bitcoin USD
27,101.28
-710.82(-2.56%)
CMC Crypto 200
590.62
-16.83(-2.77%)

AZN Oct 2023 75.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

2.8300

+0.4300

(+17.92%)

As of 10:49AM EDT. Market open.

Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.